CNBC August 20, 2024
Key Points
– Eli Lilly’s weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with pre-diabetes compared to a placebo, according to initial results from a long-term study.
– The late-stage trial on tirzepatide also found that patients experienced sustained weight loss over the roughly three-year treatment period.
– Tirzepatide is the active ingredient in the company’s highly popular weight loss injection Zepbound and diabetes drug Mounjaro.
Eli Lilly’s highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo, according to initial results from a long-term study released Tuesday.
The late-stage trial on tirzepatide,...
Today's Sponsors
Today's Sponsor